Living laboratory
grown blood vessels from the patient’s own cells
International Stem Cell Corporation (OTCBB:ISCO)
(www.intlstemcell.com),
the first company to perfect a method of creating human
"parthenogenetic" stem cells, which are derived from unfertilized human
eggs, is working with tissue engineers at Cytograft
Tissue Engineering, (Novato, CA), to design a custom cell culture
medium to cultivate living human vascular grafts; grafts which are
expected to be used in future human clinical trials.
Cytograft's living human product, called Lifeline™ (trade-name not
associated with Lifeline Cell Technology), is a promising technology
that will be used as a coronary graft for coronary bypass procedures, as
a peripheral graft to prevent lower limb amputations and as a living
tissue shunt for hemodialysis patients.
The new medium will be developed and produced by scientists at ISCO's
wholly-owned subsidiary, Lifeline Cell Technology®, a
producer of human cells and media products.
"It is an honor that Cytograft chose Lifeline Cell Technology's team to
develop their medium. Their process of growing human vascular grafts
promises to be a vast improvement over synthetic materials. Since the
grafts are grown using the patient's own cells, they will minimize the
chance of immune rejection, infection and disease transmission," said
Jeffrey Janus, CEO of Lifeline Cell Technology.
According to Todd McAllister PhD, CEO of Cytograft, "The team at
Lifeline Cell Technologies is uniquely qualified to develop and design
custom media formulations for our application. They clearly have one of
the best scientific teams in the field, and, importantly, have a service
based business model that has been flexible and responsive to our
specific requirements."
International Stem Cell Corporation (ISCO.OB) is a California
biotechnology company focused on developing therapeutic and research
products. ISCO's technology, Parthenogenesis, results in the
creation of pluripotent human stem cell lines from unfertilized human
eggs. These "parthenogenetic" stem cells can be a source of therapeutic
cells that will minimize immune rejection after transplantation into
hundreds of millions of individuals of differing sexes, ages and racial
groups. Lifeline Cell Technology develops and manufactures human cell
culture products for research into human disease and toxicology. These
products consist of human cells and low-serum or serum-free media to
grow the cells.
For more news and information on International Stem Cell Corporation
please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more. ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will minimize immune rejection after transplantation into hundreds
of millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO 760-940-6383 kaldrich@intlstemcell.com or Jeffrey
Janus, President 760-940-6383 jjanus@intlstemcell.com or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |